Jury awards Finch $25M upfront plus royalties in patent infringement verdict against Ferring

Finch Therapeutics Group, Inc.

Jury found Ferring willfully infringed on Finch/UMN patents for microbiome therapy Rebyota.
Damages include $25.0M upfront payment and $0.815M in running royalties through trial date.
Two claims (one from '309, one from '080 patents) were found invalid; remaining claims valid.
Finch expects Ferring to file post-trial motions and appeal the judgment.
Trial began Aug 5, 2024; verdict rendered Aug 9, 2024 in U.S. District Court for Delaware.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.